
David ErritzÃ,e

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5756648/publications.pdf Version: 2024-02-01



Πλυίο Ερριτζà ε

#	Article	IF	CITATIONS
1	Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry,the, 2016, 3, 619-627.	7.4	988
2	Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2138-2143.	7.1	789
3	Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 2021, 384, 1402-1411.	27.0	643
4	Psychedelics and the essential importance of context. Journal of Psychopharmacology, 2018, 32, 725-731.	4.0	357
5	Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology, 2019, 44, 1328-1334.	5.4	259
6	Increased global integration in the brain after psilocybin therapy for depression. Nature Medicine, 2022, 28, 844-851.	30.7	175
7	Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin. British Journal of Psychiatry, 2012, 200, 238-244.	2.8	170
8	Psychedelic Psychiatry's Brave New World. Cell, 2020, 181, 24-28.	28.9	162
9	Effects of psilocybin therapy on personality structure. Acta Psychiatrica Scandinavica, 2018, 138, 368-378.	4.5	156
10	Psychedelics and connectedness. Psychopharmacology, 2018, 235, 547-550.	3.1	154
11	Neural correlates of the DMT experience assessed with multivariate EEG. Scientific Reports, 2019, 9, 16324.	3.3	144
12	Therapeutic effects of classic serotonergic psychedelics: A systematic review of modernâ€era clinical studies. Acta Psychiatrica Scandinavica, 2021, 143, 101-118.	4.5	137
13	The Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labeling and Blood Oxygen Level–Dependent Resting State Functional Connectivity. Biological Psychiatry, 2015, 78, 554-562.	1.3	136
14	Neural substrates of cue reactivity and craving in gambling disorder. Translational Psychiatry, 2017, 7, e992.	4.8	134
15	DMT Models the Near-Death Experience. Frontiers in Psychology, 2018, 9, 1424.	2.1	122
16	Microdosing psychedelics: More questions than answers? An overview and suggestions for future research. Journal of Psychopharmacology, 2019, 33, 1039-1057.	4.0	121
17	Endogenous Opioid Release in the Human Brain Reward System Induced by Acute Amphetamine Administration. Biological Psychiatry, 2012, 72, 371-377.	1.3	104
18	Cerebral serotonin transporter binding is inversely related to body mass index. NeuroImage, 2010, 52, 284-289.	4.2	96

David ErritzÃ,e

#	Article	IF	CITATIONS
19	Blunted Endogenous Opioid Release Following an Oral Amphetamine Challenge in Pathological Gamblers. Neuropsychopharmacology, 2016, 41, 1742-1750.	5.4	96
20	The Center for Integrated Molecular Brain Imaging (Cimbi) database. NeuroImage, 2016, 124, 1213-1219.	4.2	95
21	Self-blinding citizen science to explore psychedelic microdosing. ELife, 2021, 10, .	6.0	94
22	Brain serotonin 2A receptor binding: Relations to body mass index, tobacco and alcohol use. Neurolmage, 2009, 46, 23-30.	4.2	87
23	Amphetamine induced endogenous opioid release in the human brain detected with [11C]carfentanil PET: replication in an independent cohort. International Journal of Neuropsychopharmacology, 2014, 17, 2069-2074.	2.1	85
24	Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression. Frontiers in Pharmacology, 2021, 12, 788155.	3.5	77
25	In Vivo Imaging of Cerebral Serotonin Transporter and Serotonin2A Receptor Binding in 3,4-Methylenedioxymethamphetamine (MDMA or "Ecstasyâ€) and Hallucinogen Users. Archives of General Psychiatry, 2011, 68, 562.	12.3	76
26	Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing. Scientific Reports, 2021, 11, 1941.	3.3	76
27	The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories. International Journal of Neuropsychopharmacology, 2014, 17, 527-540.	2.1	75
28	Cortical and Subcortical 5-HT2A Receptor Binding in Neuroleptic-Naive First-Episode Schizophrenic Patients. Neuropsychopharmacology, 2008, 33, 2435-2441.	5.4	64
29	In Vivo Imaging of Cerebral Dopamine D3 Receptors in Alcoholism. Neuropsychopharmacology, 2014, 39, 1703-1712.	5.4	53
30	A Nonlinear Relationship between Cerebral Serotonin Transporter and 5-HT _{2A} Receptor Binding: An <i>In Vivo</i> Molecular Imaging Study in Humans. Journal of Neuroscience, 2010, 30, 3391-3397.	3.6	52
31	Familial Risk for Mood Disorder and the Personality Risk Factor, Neuroticism, Interact in Their Association with Frontolimbic Serotonin 2A Receptor Binding. Neuropsychopharmacology, 2010, 35, 1129-1137.	5.4	49
32	Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans. Journal of Psychopharmacology, 2021, 35, 459-468.	4.0	40
33	Psychedelics and health behaviour change. Journal of Psychopharmacology, 2022, 36, 12-19.	4.0	40
34	Recreational use of psychedelics is associated with elevated personality trait openness: Exploration of associations with brain serotonin markers. Journal of Psychopharmacology, 2019, 33, 1068-1075.	4.0	37
35	Serotonin release measured in the human brain: a PET study with [11C]CIMBI-36 and d-amphetamine challenge. Neuropsychopharmacology, 2020, 45, 804-810.	5.4	34
36	Study Protocol for "Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study― Frontiers in Psychiatry, 2021, 12, 735523.	2.6	33

David ErritzÃ,e

#	Article	IF	CITATIONS
37	Simultaneous polysubstance use among Danish 3,4â€methylenedioxymethamphetamine and hallucinogen users: combination patterns and proposed biological bases. Human Psychopharmacology, 2012, 27, 352-363.	1.5	31
38	Can pragmatic research, real-world data and digital technologies aid the development of psychedelic medicine?. Journal of Psychopharmacology, 2022, 36, 6-11.	4.0	28
39	Positron emission tomography and single photon emission CT molecular imaging in schizophrenia. Neuroimaging Clinics of North America, 2003, 13, 817-832.	1.0	26
40	Altered Insula Connectivity under MDMA. Neuropsychopharmacology, 2017, 42, 2152-2162.	5.4	25
41	Evidence for GABAâ€A receptor dysregulation in gambling disorder: correlation with impulsivity. Addiction Biology, 2017, 22, 1601-1609.	2.6	24
42	Sustained, Multifaceted Improvements in Mental Well-Being Following Psychedelic Experiences in a Prospective Opportunity Sample. Frontiers in Psychiatry, 2021, 12, 647909.	2.6	21
43	In abstinent MDMA users the cortisol awakening response is off-set but associated with prefrontal serotonin transporter binding as in non-users. International Journal of Neuropsychopharmacology, 2014, 17, 1119-1128.	2.1	16
44	Acute effects of MDMA on trust, cooperative behaviour and empathy: A double-blind, placebo-controlled experiment. Journal of Psychopharmacology, 2021, 35, 547-555.	4.0	15
45	Are ecstasy induced serotonergic alterations overestimated for the majority of users?. Journal of Psychopharmacology, 2018, 32, 741-748.	4.0	14
46	Psychedelic experience dose-dependently modulated by cannabis: results of a prospective online survey. Psychopharmacology, 2022, 239, 1425-1440.	3.1	13
47	Examining Psychedelic-Induced Changes in Social Functioning and Connectedness in a Naturalistic Online Sample Using the Five-Factor Model of Personality. Frontiers in Psychology, 2021, 12, 749788.	2.1	13
48	Lessons to be learned from early psychedelic therapy in Denmark. Nordic Journal of Psychiatry, 2017, 71, 487-488.	1.3	10
49	Concerns regarding conclusions made about LSD-treatments (received 25 October 2016). History of Psychiatry, 2017, 28, 257-260.	0.3	8
50	Chronic alcohol exposure differentially modulates structural and functional properties of amygdala: A crossâ€sectional study. Addiction Biology, 2021, 26, e12980.	2.6	2
51	Seasonal changes in brain serotonin transporter binding in short 5-HTTLPR-allele carriers but not in long-allele homozygotes. Nature Precedings, 2008, , .	0.1	Ο